ReviewMolecular medicine reports2026
Mucin 2 and unfolded protein response reshape the mucus barrier in inflammatory bowel disease (Review).
Review in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Host metabolism shapes the intestinal microbiota: a top-down paradigm of environmental selection pressure.Gut microbes · 2026Review
- Integrated Proteomic Profiling Reveals Dynamic Remodeling of the Intestinal Proteome inBiology · 2026Article
- Natural Polysaccharide-Mediated Nano-Delivery Systems for Osteoporosis Therapy From a Gut-Bone Axis Regulatory Perspective.Advanced healthcare materials · 2026Review
- Review
- Article
- Protopanaxatriol enhances mucin expression in intestinal epithelial cells and mice.Journal of ginseng research · 2026Article
- Novel Perspectives on the Relationship Between the Gastrointestinal Mucus Barrier and Soybean Agglutinin.Cells · 2026Review
- The Power of MUC2 in Mucinous Adenocarcinomas.Pathobiology : journal of immunopathology, molecular and cellular biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucin 2 (MUC2) is the primary structural component of the intestinal mucus layer and is essential for maintaining the integrity of the mucus barrier and influencing the development of inflammatory bowel disease (IBD). Disruption of MUC2 production or secretion compromises barrier function, increasing susceptibility to the chronic mucosal inflammation characteristic of IBD. Given their large size and complex folding requirements, immature MUC2 precursors easily accumulate in the endoplasmic reticulum (ER) and cause ER stress, leading to activation of the unfolded protein response (UPR). The UPR restores ER homeostasis by reducing protein synthesis, enhancing folding, and degrading misfolded proteins. The mammalian UPR has three known signaling branches: Pancreatic ER kinase, ER transmembrane inositol‑requiring enzymes 1α and β (IRE1α and IRE1β) and activating transcription factor 6. Anterior gradient 2 (AGR2) is a dimeric protein disulfide isomerase family member involved in the regulation of protein quality control in the ER. Importantly, IRE1β‑AGR2 signaling potentially serves as a superior regulatory mechanism for controlling UPR activation caused by the misfolding of MUC2 in goblet cells. The present review highlights the critical role of MUC2 dysfunction and UPR imbalance in IBD pathogenesis. Targeting the association between novel UPR signaling pathways and restoring MUC2 protein function may provide new insights into IBD research and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.